Veracyte, Inc. (VCYT): EBITDA
$79.19M
Year ended 2025-12-31
$126.60M
Trailing 12 months to 2026-06-30
| Period ended | EBITDA | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $79.19M | +100.0% | 2026-02-26, From 2025-01-01 |
| 2024-12-31 | $39.60M | n/m | 2026-02-26, From 2024-01-01 |
| 2023-12-31 | -$58.61M | n/m | 2026-02-26, From 2023-01-01 |
| 2022-12-31 | -$15.15M | n/m | 2025-02-28, From 2022-01-01 |
| 2021-12-31 | -$62.31M | n/m | 2024-02-29, From 2021-01-01 |
| 2020-12-31 | -$27.45M | n/m | 2023-03-01, From 2020-01-01 |
| 2019-12-31 | -$11.01M | n/m | 2022-02-28, From 2019-01-01 |
| 2018-12-31 | -$18.31M | n/m | 2021-02-22, From 2018-01-01 |
| 2017-12-31 | -$22.70M | n/m | 2020-02-25, From 2017-01-01 |
| 2016-12-31 | -$25.29M | n/m | 2019-02-25, From 2016-01-01 |
| 2015-12-31 | -$31.21M | n/m | 2018-02-27, From 2015-01-01 |
| 2014-12-31 | -$27.83M | n/m | 2017-03-01, From 2014-01-01 |
| 2013-12-31 | -$22.17M | n/m | 2016-03-14, From 2013-01-01 |
| 2012-12-31 | -$18.22M | n/m | 2015-03-25, From 2012-01-01 |
| 2011-12-31 | -$14.65M | n/a | 2014-03-20, From 2011-01-01 |
EBITDA at similar companies
| Company | Year ended | EBITDA | Change YoY |
|---|---|---|---|
| Veracyte, Inc. (VCYT) | 2025-12-31 | $79.19M | +100.0% |
| CareDx, Inc. (CDNA) | 2025-12-31 | -$15.76M | n/m |
| Castle Biosciences Inc (CSTL) | 2025-12-31 | -$2.04M | n/m |
| Caris Life Sciences, Inc. (CAI) | 2025-12-31 | $67.73M | n/m |
| Fulgent Genetics, Inc. (FLGT) | 2025-12-31 | -$66.97M | n/m |
| BillionToOne, Inc. (BLLN) | 2025-12-31 | $22.92M | n/m |
| Guardant Health, Inc. (GH) | 2025-12-31 | -$397.51M | n/m |
| RadNet, Inc. (RDNT) | 2025-12-31 | $198.09M | -13.8% |
| Natera, Inc. (NTRA) | 2025-12-31 | -$268.15M | n/m |
Compare VCYT, CDNA, CSTL, CAI side by side · Screen every company in Services-Medical Laboratories ↗